Fri.Nov 08, 2024

article thumbnail

Daiichi Sankyo links up with Korea's Alteogen on subcutaneous Enhertu in $300M licensing deal

Fierce Pharma

A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be in the works from Korea’s Alteogen following a licensing deal worth up to | Alteogen will use its human hyaluronidase hybridization platform to develop a subcutaneous formulation of the blockbuster antibody-drug conjugate.

143
143
article thumbnail

Moderna Bivalent COVID-19 Vaccine More Effective at Preventing Hospitalization in High-Risk Patients Compared With Pfizer-BioNTech Vaccine

Pharmacy Times

Though both vaccines remain effective at preventing severe illness, Moderna’s mRNA-1273.222 vaccine was found to be significantly more effective among adults with underlying medical conditions.

Vaccines 132
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: Pharma giant GSK is quitting BIO in latest setback for the lobbying group

STAT

WASHINGTON — Pharmaceutical industry giant GSK plans to depart the biotechnology industry’s largest trade group, the Biotechnology Innovation Organization.

142
142
article thumbnail

Presbyterian Healthcare Services taps RhythmX AI to roll out gen AI copilots for primary care

Fierce Healthcare

The U.S. faces a critical shortage of primary care physicians, and the labor crunch is projected to get worse. | The company is working with New Mexico-based Presbyterian Healthcare Services to pilot its primary care AI pilot.

132
132
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

FDA Grants Orphan Drug Designation to Ifetroban for Treatment of Duchenne Muscular Dystrophy-Associated Cardiomyopathy

Pharmacy Times

The drug is being investigated for its potential to reduce fibrosis associated with muscular dystrophy that can cause scarring of the heart tissue.

FDA 131
article thumbnail

Why Oscar Health co-founder Mario Schlosser is bullish on ICHRA

Fierce Healthcare

LAS VEGAS — Employers' healthcare costs continue to rise, leading them to seek new alternatives to drive down expenses while avoiding steps to shift additional costs to workers. | In response to rising costs, some in the industry have been beating the drum for individual coverage health reimbursement arrangements, or ICHRA.

127
127

More Trending

article thumbnail

Eisai dials back forecasts for Alzheimer's drug Leqembi

pharmaphorum

Eisai has scaled down its sales expectations for Alzheimer's disease drug Leqembi after sluggish sales growth in the first half of the current fiscal year.

124
124
article thumbnail

GSK calls it quits on trade group BIO for 2025, following exits by Takeda, UCB and more

Fierce Pharma

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), following a string of exits by companies including Pfizer, UCB, WuXi AppTec and | The company opted not to renew its membership for 2025 following an annual review of its trade group associations, a spokesperson said.

119
119
article thumbnail

Corresponding Responsibility of Pharmacies, DEA to Uphold Controlled Substances Act | ASPL 2024

Drug Topics

Joel Ferre, JD, Assistant United States Attorney in Utah, led a discussion covering the DEA and pharmacies’ roles in reporting red flags when dispensing medication.

article thumbnail

Opinion: What the 2024 election looks like from the therapist’s room

STAT

I am standing in front of my bathroom mirror trying to control my breathing. It is the morning after the election, and I learned the results when I woke about one hour ago. I had gotten up, showered, dressed, prepared breakfast and school lunches, ran to school drop-off, and returned home, a bit of a wreck with a few minutes to spare.  I look down at my watch.

116
116
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

How to conduct a cybersecurity audit on your pharma supply chain

pharmaphorum

Conducting a cybersecurity audit on your pharmaceutical supply chain is crucial for protecting sensitive data. Learn how to properly assess and strengthen your cybersecurity measures with this guide.

109
109
article thumbnail

STAT+: Pharmalittle: We’re reading about FDA plans to ban a cold med; Eisai Alzheimer’s drug sales, and more

STAT

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather modest. We expect to continue the never-ending quest to manicure the Pharmalot grounds, promenade with the official mascots, and catch up on napping. We also hope to hold another listening party, where the rotation will likely include this , this , this , this and this.

FDA 110
article thumbnail

AZ confirms China president has been detained

pharmaphorum

AstraZeneca has revealed that its top executive in China, Leon Wang, has been detained by Chinese authorities

137
137
article thumbnail

Escaped monkeys and who to know in the MAHA world

STAT

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds.  Sign up here. If you’re in the market for a heartwarming story, look no further than this “real life rom com ” as related on Threads. (My heart, like the person who posted it, is about to burst).

FDA 106
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

It’s time to end America’s testosterone paranoia

pharmaphorum

Explore the controversial issue of Testosterone Deficiency Syndrome (TDS) and the impact of America's testosterone paranoia with insightful analysis and perspectives on the topic.

105
105
article thumbnail

STAT+: Up and down the ladder: The latest comings and goings

STAT

Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others.  That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which we highlight a different person each week.

106
106
article thumbnail

Ensuring product authenticity in the pharmaceutical industry with cloud technology

pharmaphorum

Implementing cloud technology can help ensure the authenticity of pharmaceutical products like Ozempic, used for type 2 diabetes treatment. Learn how this technology is enhancing product security in the pharmaceutical industry generally.

104
104
article thumbnail

AstraZeneca, Amgen's Tezspire scores in rhinosinusitis study

Fierce Pharma

Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that AstraZeneca and Amgen's Tezspire provided a statistically significant and clinically meaningful reduction in polyp size and nasal congestion in patients with severe chronic rhinosinusitis with nasal polyps.

100
100
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

NHS Wales partners with Illumina on genomics drive

pharmaphorum

Wales has extended a scheme to harness the power of genomics to improve cancer care and prevention via an alliance with gene-sequencing giant Illumina.

105
105
article thumbnail

FDA proposes ban on main ingredient in many OTC decongestants

Fierce Pharma

Common oral medicines that have been used for decades as decongestants such as Sudafed, NyQuil and Benadryl may soon be cleared from shelves as the FDA has

FDA 104
article thumbnail

Daiichi Sankyo partners Alteogen on subcutaneous Enhertu

pharmaphorum

Daiichi Sankyo signs a $300m deal with Alteogen to develop a subcutaneous version of anti-HER2 cancer drug Enhertu.

118
118
article thumbnail

J&J angles Darzalex for first move into early-stage myeloma with trial win, FDA filing

Fierce Pharma

After a positive phase 3 trial, Johnson & Johnson hopes its Darzalex could become the first treatment option for patients with smoldering multiple myeloma, an early-stage form of the blood diso | After a positive phase 3 trial, Johnson & Johnson hopes its Darzalex could become the first treatment option for patients with smoldering multiple myeloma, an early-stage form of the blood disorder.

FDA 132
article thumbnail

AstraZeneca and Amgen’s Tezspire succeeds in Phase III nasal polyps trial

Pharmaceutical Technology

A Phase III trial with the companies’ monoclonal antibody in patients with chronic rhinosinusitis with nasal polyps met its primary endpoint.

105
105
article thumbnail

Transforming CLL Management: Pharmacists' Impact on Treatment Strategies, Adherence, and Quality of Life

Pharmacy Times

Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.

93
article thumbnail

Ultra-processed food is causing a boom for obesity drug Ozempic

Pharmaceutical Technology

The seemingly inexorable rise in global obesity is being reflected in the sales of diabetes and weight-loss drugs, including Ozempic.

105
105
article thumbnail

Expert: Independent Pharmacies Express Unique Value to Providers, Community

Pharmacy Times

Tripp Logan, PharmD, reflects on being named Independent Pharmacist of the Year from the National Community Pharmacists Association.

article thumbnail

What RFK Jr.’s influence could mean for pharma

PharmaVoice

Past comments hint at the changes Robert F. Kennedy Jr. could make across the various sectors of healthcare.

111
111
article thumbnail

Understanding the Burnout Crisis Among Student Pharmacists

Pharmacy Times

The demanding nature of pharmacy programs often leaves little time for self-care, social activities, or hobbies, leading to an imbalance that can foster burnout.

94
article thumbnail

UK health data ecosystem 'is hampering research'

pharmaphorum

The UK is squandering the vast resource of NHS patient data because too many obstacles are being placed in front of researchers trying to tap into it – holding back medical advances. That is the conclusion of the much-anticipated Sudlow Review – carried out by Prof Cathie Sudlow, chief scientist of Health Data Research (HDR) UK – which found that accessing patient data can take months or even years, hampering research into areas like dementia, cancer and heart disease.

85
article thumbnail

Eisai lowers Leqembi revenue forecast after rocky entry to market

Pharmaceutical Technology

Leqembi is approved for Alzheimer’s patients in multiple territories, but questions remain over its cost-effectiveness.

96
article thumbnail

Telehealth company Boulder Care raises profile with prominent executive hires

Fierce Healthcare

Boulder Care, a telehealth addiction treatment company, is positioning itself to follow in the footsteps of major telehealth players like Livongo, Teladoc and Brightline. | Following a $35 million series C round in May, Boulder Care has invested in two new executive hires, Mitzi Yue and Meena Narayanan. Both come from top name digital health companies.

76
article thumbnail

Off-Label Semaglutide Linked to Deaths, Hospitalizations Calling for Compounding Regulation

Pharmacy Times

Off-label semaglutide has been linked to serious adverse effects, calling for increased regulation around compounding.

article thumbnail

Future Fields looks to solve industry's biomanufacturing woes with fruit fly-based protein production

Fierce Pharma

With biomanufacturing often a limiting factor for drug developers, Canada’s Future Fields is heralding its bug-based approach to protein production as a potential salve. | With biomanufacturing often a limiting factor for drug developers, Canada’s Future Fields is heralding its bug-based approach to protein production as a potential salve. Now, after several years spent validating its manufacturing platform, the company is expanding in a big way with the debut of a new service line and factory i

72